Table 3. Comparison between VDRL and TPHA titers in syphilis patients with and without HIV.
Syphilis |
VDRL |
TPHA |
||
HIV (+) |
HIV (-) |
HIV (+) |
HIV (-) |
|
Baseline |
||||
Mean ± SD |
1:151 ± 1:379 |
1:23 ± 1:32 |
1:13,254 ± 1:15,810 |
1:2,993 ± 1:4,287 |
Median (range) |
1:64 (1:2-1:2,048) |
1:16 (1:2-1:128) |
1:5,120 (1:320-1:40,960) |
1:2,560 (1:80-1:20,480) |
p-value |
0.001 |
0.002 |
||
1 Month Follow-Up After Therapy |
||||
Mean ± SD |
1:45 ± 1:44 |
1:11 ± 1:14 |
1:6,562 ± 1:10,739 |
1:3,260 ± 1:5,291 |
Median (range) |
1:32 (1:2-1:128) |
1:4 (0-1:64) |
1:2,560 (1:128-1:40,960) |
1:1280 (0-1:20,480) |
p-value |
0.001 |
0.082 |
||
Last Follow-Up After Therapy |
||||
Mean ± SD |
1:45 ± 1:44 |
1:11 ± 1:14 |
1:6,562 ± 1:10,739 |
1:3,260 ± 1:5,291 |
Median (range) |
1:32 (1:2-1:128) |
1:4 (0-1:64) |
1:2,560 (1:128-1:40,960) |
1:1280 (0-1:20,480) |
p-value |
0.001 |
0.018 |